Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation (NIRSMED)
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
During clamping of one internal carotid artery for endarterectomy, blood flow through this vessel has to be compensated by collateral arteries including the contralateral internal artery and vertebral arteries. In 7 % of all patients undergoing carotid endarterectomy this collateral flow is not sufficient to maintain adequate cerebral perfusion during clamping and ischemic brain damage is likely to emerge. To maximize cerebral blood flow during clamping, increase of blood pressure is a common procedure and routine at our institution. Increasing blood pressure can be enabled by tapering a mixture of Cafedrine und Theodrenalin (Akrinor®) until the designated blood pressure is reached. After declamping, the blood pressure has to be reduced to normal values to avoid postoperative hyperperfusion syndrome. This is enabled by tapering urapidil until normal blood pressure is achieved.
It has been shown that cerebral oxygenation measured by near infrared spectroscopy is reduced by intravenous application of norepinephrine. Otherwise, intravenous nitroglycerine increases cerebral oxygenation during cardiopulmonary bypass. Hence, cafedrine/theodrenalin and urapidil may also have an effect on cerebral perfusion. In this prospective randomized study the effect of cafedrine/theodrenalin and urapidil on cerebral oxygenation measured by near infrared spectroscopy is investigated.
| Condition | Intervention |
|---|---|
|
Cerebral Ischemia |
Drug: cafedrine/theodrenaline, urapidil |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effect of Cafedrine/Theodrenaline and Urapidil During Carotid Endarterectomy on Cerebral Oxygenation Measured by Near Infrared Spectroscopy |
- Cerebral oxygenation [ Time Frame: 1 hour ] [ Designated as safety issue: No ]Outcome measure is change of cerebral oxygenation measured by near-infrared spectroscopy from values at baseline (arterial blood pressure in normal range) to values three minutes after increasing systolic blood pressure above 160 mmHg by intravenous injection of cafedrin/theodrenalin as needed (0,5 - 1 ml).
| Estimated Enrollment: | 80 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: cafedrine/theodrenalin |
Drug: cafedrine/theodrenaline, urapidil
Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients scheduled for carotid endarterectomy
Exclusion Criteria:
- Cerebral disease
Contacts and Locations| Contact: Axel Axel, Dr. | 0049(0)4315972991 | fudickar@anaesthesie.uni-kiel.de |
| Germany | |
| University Hospital Schleswig-Holstein, Campus Kiel | Not yet recruiting |
| Kiel, Schleswig-Holstein, Germany, 24105 | |
| Contact: Axel Fudickar, Dr. 0049(0)4315972991 fudickar@anaesthesie.uni-kiel.de | |
More Information
No publications provided
| Responsible Party: | Dr. Axel Fudickar, University Hospital Schleswig-Holstein, Campus Kiel |
| ClinicalTrials.gov Identifier: | NCT01311414 History of Changes |
| Other Study ID Numbers: | Fudickar6 |
| Study First Received: | March 7, 2011 |
| Last Updated: | March 8, 2011 |
| Health Authority: | Germany: Ethics Commission |
Additional relevant MeSH terms:
|
Cerebral Infarction Brain Ischemia Ischemia Brain Infarction Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Stroke Vascular Diseases Cardiovascular Diseases Pathologic Processes Norepinephrine Urapidil Theophylline |
Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists |
ClinicalTrials.gov processed this record on May 16, 2013